Benfotiamine: study protocols
20 study groups say how much Benfotiamine participants took a day. These are the doses the studies gave. They are not a recommendation.
Dose per serving from products
433 products in our catalogue print how much Benfotiamine a serving holds.
Most common: 250 mg to 500 mg, 29% of 433 products.
| Dose per serving | Products |
|---|---|
| 500 mcg or less | 17 |
| 500 mcg to 1 mg | 10 |
| 1 mg to 2.5 mg | 7 |
| 2.5 mg to 5 mg | 10 |
| 5 mg to 10 mg | 12 |
| 10 mg to 25 mg | 52 |
| 25 mg to 50 mg | 42 |
| 50 mg to 100 mg | 33 |
| 100 mg to 250 mg | 87 |
| 250 mg to 500 mg | 126 |
| 500 mg to 1 g | 37 |
Dose per serving from research
20 study groups in 11 studies say how much Benfotiamine participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 500 mg to 1 g, 35% of 20 study groups.
| Daily dose | Study groups |
|---|---|
| 50 mg to 100 mg | 2 |
| 100 mg to 250 mg | 5 |
| 250 mg to 500 mg | 4 |
| 500 mg to 1 g | 7 |
| 1 g to 2.5 g | 2 |
Commonly used together
2 of 20 study groups took Benfotiamine with something else, but nothing that 3 or more different studies gave.
20 study groups
| Study | |||
|---|---|---|---|
| Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study 2008 · Benfotiamine 300 mg per day · Patients with symmetrical, distal diabetic polyneuropathy; ages and sex not reported | 300 mg | 6 weeks | 45 |
| Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study) 2005 · benfotiamine group · Adults aged 18–70 with type 1 or type 2 diabetes and diabetic polyneuropathy of no longer than two years’ duration | 200 mg | 3 weeks | 20 |
| Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy 1999 · benfotiamine monotherapy · Adults aged 40–70 with painful peripheral diabetic neuropathy and HbA1c <8.0% | 150 mg | 6 weeks | 12 |
| Double-blind, randomized placebo-controlled clinical trial of benfotiamine for severe alcohol dependence 2013 · 600 mg BF once daily by mouth · Adults aged 21–59 with current alcohol use disorder and active alcohol use or less than 30 days of abstinence | 600 mg | 24 weeks | 60 |
| Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study 2008 · Benfotiamine 600 mg per day · Patients with symmetrical, distal diabetic polyneuropathy; ages and sex not reported | 600 mg | 6 weeks | 47 |
| Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial 2020 · benfotiamine treatment group · Adults aged 60 years or older with amyloid-positive amnestic mild cognitive impairment or mild dementia due to Alzheimer’s disease | 600 mg | 1 year | 34 |
| Therapeutic efficacy of "Milgamma" in patients with painful diabetic neuropathy 1997 · Milgamma group · Adults with diabetes and painful peripheral polyneuropathy | 200 mg | 90 days | 30 |
| Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy 1999 · high-dose benfotiamine–vitamin B combination · Adults aged 40–70 with painful peripheral diabetic neuropathy and HbA1c <8.0% | 320 mg | 6 weeks | 12 |
| Change in psychiatric symptomatology after benfotiamine treatment in males is related to lifetime alcoholism severity 2015 · benfotiamine · Adult males aged 21–59 with current alcohol use disorder and active alcohol use or fewer than 30 days of abstinence | 600 mg | 24 weeks | — |
| Efficacy and tolerability of advanced glycation end-products inhibitor in osteoarthritis: a randomized, double-blind, placebo-controlled study 2013 · AGEs inhibitor (drug) group · Adults with primary osteoarthritis meeting American College of Rheumatology classification criteria; mean age 57.26 years; 26 women and 4 men in the study overall | 150 mg | 24 weeks | — |
| Alteration of thiamine pharmacokinetics by end-stage renal disease (ESRD) 1999 · benfotiamin group · Adults with end-stage renal disease | 100 mg | 1 day | — |
| High thiamine diphosphate concentrations in erythrocytes can be achieved in dialysis patients by oral administration of benfontiamine 2000 · benfotiamine group · Adults with end-stage renal disease; age and sex not stated | 100 mg | 1 day | — |
| Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects 2021 · MAD 150 mg · Healthy Chinese men and women aged 18–45 years | 300 mg | 10 days | 12 |
| Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects 2021 · MAD 300 mg · Healthy Chinese men and women aged 18–45 years | 600 mg | 10 days | 12 |
| Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects 2021 · MAD 600 mg · Healthy Chinese men and women aged 18–45 years | 1.2 g | 10 days | 12 |
| Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects 2021 · SAD 150 mg · Healthy Chinese men and women aged 18–45 years | 150 mg | 1 day | 10 |
| Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects 2021 · SAD 300 mg · Healthy Chinese men and women aged 18–45 years | 300 mg | 1 day | 10 |
| Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects 2021 · SAD 600 mg · Healthy Chinese men and women aged 18–45 years | 600 mg | 1 day | 10 |
| Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects 2021 · SAD 900 mg · Healthy Chinese men and women aged 18–45 years | 900 mg | 1 day | 10 |
| Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects 2021 · SAD 1200 mg · Healthy Chinese men and women aged 18–45 years | 1.2 g | 1 day | 10 |